The effects of two different sedation protocols during transvaginal oocyte retrieval will be investigated on propofol consumption as a rescue sedative and on IVF success. One group will receive dexmedetomidine and fentanyl while the other will receive midazolam and remifentanil.
Women will be consecutively allocated into one of the following two groups using a 1:1 ratio in order to avoid any potential source of bias. Group DEX: women will receive dexmedetomidine (solution 4 γ/ml) continuously infused at a dose of 1 γ/kg/ and fentanyl 100γ iv. Dexmedetomidine infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of procedure. At that time point, both total volume (ml) and dose (γ) of dexmedetomidine administered will be recorded. Group MZM: women will receive remifentanil (solution 50γ/ml) continuously infused at a dose of 0.2 γ/kg/min και midazolam 1 mg iv. Remifentanil infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure. At that time point, both total volume (ml) and dose (γ) of remifentanil administered will be recorded. In both groups, in case of non-co-operation of the woman (e.g. kinetic response), propofol will be given as a bolus rescue dose as follows: the 1st rescue dose will be 1mg/kg while all the next doses will be 0.5 mg/kg. At the end of the procedure, the number of rescue doses and the total rescue dose (mg) of propofol given will be recorded. Intraoperative monitoring will include ECG, noninvasive blood pressure, SpO2, EtCO2 and depth of sedation using BIS values and ΟΑSS scale. Also, adverse effects such as hypotension, bradycardia, nausea \& vomiting, rigidity, airway obstruction, and need for bag-mask ventilation will be recorded. The use of vasoactive drugs will also be reported. At the end of the procedure, the time and quality of recovery will be assessed using ΟΑSS scale (max score=5), while postoperatively the Post Anesthesia Discharge Scoring System, as well as woman's and gynecologist's (physician) overall satisfaction related to the sedation techniques used, will be recorded. Regarding the IVF outcome, the following parameters will be recorded: number of oocytes retrieved, the percentage of mature oocytes, embryo quality, percentage of positive pregnancy test, percentage of clinical pregnancy, the percentage of live birth.
Study Type
OBSERVATIONAL
Enrollment
80
sedation for oocyte retrieval
Attikon University Hospital
Athens, Attica, Greece
propofol consumption
difference \>30% in propofol consumption
Time frame: from the beginning to the end of the transvaginal oocyte retrieval procedure
number of oocytes retrieved
Time frame: up to 3 weeks after starting ovarian stimulation treatment
percentage of mature oocytes
Time frame: up to 3 weeks after starting ovarian stimulation treatment
fertilization rate
Time frame: up to 3 weeks after starting ovarian stimulation treatment
embryo quality
Embryo quality for endometrial transfer or cryopreservation will be assessed according to morphological criteria based on the overall blastomere number, size, appearance and degree of fragmentation
Time frame: up to 4 weeks after starting ovarian stimulation treatment
positive pregnancy test
Time frame: up to 3 weeks after transvaginal oocyte retrieval
clinical pregnancy
confirmed presence of an intrauterine sac with fetal heart activity through transvaginal ultrasound scan at seven weeks of gestation, following a positive serum β-hCG test
Time frame: up to 12 weeks after starting ovarian stimulation treatment
Live birth
birth of a live fetus after 20 weeks of gestation
Time frame: up to 24 weeks after starting ovarian stimulation treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
BIS score
bispectral index score
Time frame: assessed every 5 minutes during transvaginal oocyte retrieval procedure
Observer's Assessment of Alertness/Sedation scale - OAA/S scale
used to assess level of sedation during the procedure (5- Responds readily to name spoken in normal tone, 4-Lethargic response to name spoken in normal tone, 3-Responds only after name is called loudly and/or repeatedly, 2-Responds only after mild prodding or shaking, 1-Does not respond to mild prodding or shaking
Time frame: assessed every 5 minutes during transvaginal oocyte retrieval procedure
airway obstruction
(yes/no)
Time frame: during the procedure
need to ventilate by mask
yes/no
Time frame: during the procedure
presence of muscle rigidity
yes/no
Time frame: during the procedure
presence of bradycardia (heart rate less than 50 bpm)
Time frame: during the procedure
hypotension (mean arterial pressure lower than 65 mmHg) for more than 1' during procedure
Time frame: during the procedure
dexmedetomidine consumption
total μg
Time frame: from the beginning to the end of the transvaginal oocyte retrieval procedure
remifentanil consumption
total μg
Time frame: from the beginning to the end of the transvaginal oocyte retrieval procedure
vasoactive drug consumption
Time frame: from the beginning to the end of the transvaginal oocyte retrieval procedure
patient satisfaction score
4 point scale (0-poor, 1-good, 2-very good, 3-excellent)
Time frame: end of procedure
physician satisfaction score
4 point scale (0-poor, 1-good, 2-very good, 3-excellent)
Time frame: end of procedure
presence of nausea or vomitus
0-none, 1-nausea, 2-vomitus\<2, 3 vomitus\>2
Time frame: from end of procedure to discharge from hospital, approximately 4 hours after procedure
Post Hospital Discharge Score
time required by patient to be able to return at home
Time frame: from end of procedure to discharge from hospital, approximately 4 hours after procedure